New Zealand - English - Medsafe (Medicines Safety Authority)

centre for advanced medicine - ascorbic acid 500 mg/ml;  ;   - solution for injection - 500 mg/ml - active: ascorbic acid 500 mg/ml     excipient: disodium edetate dihydrate nitrogen sodium bicarbonate sodium hydroxide water for injection - ascor l 500 is indicated for ascorbic acid deficiency. parenteral ascorbic acid supplementation may be necessary in the treatment of scurvy for patients with gastric disorders, for patients with extensive injuries, for surgical patients and others only if their needs cannot be met from normal dietary sources or in patients who cannot take oral vitamins. acute ascorbic acid deficiency may be associated with extensive injuries and other states of extreme stress. vitamin c requirements are also significantly increased in certain diseases and conditions such as tuberculosis, hyperthyroidism, peptic ulcer, neoplastic disease and lactation.

New Zealand - English - Medsafe (Medicines Safety Authority)

centre for advanced medicine - disodium edetate 150 mg/ml (added as disodium edetate hydrous 166mg) - solution for injection - 150 mg/ml - active: disodium edetate 150 mg/ml (added as disodium edetate hydrous 166mg) excipient: hydrochloric acid sodium hydroxide water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

centre for advanced medicine - disodium edetate 150 mg/ml (added as disodium edetate hydrous 166mg) - solution for injection - 150 mg/ml - active: disodium edetate 150 mg/ml (added as disodium edetate hydrous 166mg) excipient: hydrochloric acid sodium hydroxide water for injection

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

aether centre (beijing) biology co., limited, china - ivermectin - injection - 10

Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - goserelin, quantity: 10.8 mg - implant - excipient ingredients: polyglactin - for the treatment of advanced prostate cancer. bicalutamide is also indicated for the prevention of disease flare associated with initial goserelin treatment

Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - goserelin, quantity: 3.6 mg - implant - excipient ingredients: polyglactin - for the treatment of advanced prostate cancer. bicalutamide is also indicated for the prevention of disease flare associated with initial goserelin treatment.

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

aether centre (beijing) biology co., ltd., china - oxytetracycline hydrochloride - injection - 100 mg/ml

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

aether centre (beijing) biology co., ltd., china - florfenicol injection 30% - injection - 300

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

aether centre (beijing) biology co., limited, china - oxytetracycline hydrochloride - injection - 100 mg/ml

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

aether centre (beijing) biology co., limited, china - florfenicol - injection - 300